Overview
Dr. William H. Sharfman is an associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous oncology, dermatology and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program. He earned his M.D. from the University of Toledo College of Medicine. He completed his residency at Cleveland Clinic and performed a fellowship in hematology and oncology at Cleveland Clinic. Dr. Sharfman's research interests include novel therapies for high risk and advanced melanoma patients.
Dr. Sharfman is rated as an Elite provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, and Familial Pancreatic Cancer.
His clinical research consists of co-authoring 52 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 33 articles and participated in 2 clinical trials in the study of Melanoma.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER COMMERCIAL
- OTHER MEDICARE PART D
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER MEDICARE
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
Pavilion III STE 1500, Lutherville, MD 21093
201 North Broadway Street, Viragh BLDG 5th FL, Baltimore, MD 21287
Additional Areas of Focus
Dr. Sharfman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
3 Clinical Trials
Skip Viragh Outpatient Cancer Center
Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer, and the first description of kidney retransplantation performed after immunotherapy–related organ rejection. Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. Results from this trial - the first of its kind - were reported in 2022 at an international oncology meeting. Dr. Lipson is a leader in the clinical development of relatlimab, an antibody blocking the LAG-3 immune checkpoint. He leads a phase 2 trial testing combination immune checkpoint inhibitor therapy—including anti-LAG-3—for patients with advanced basal cell carcinoma. In June 2021, Dr. Lipson presented findings from the first phase 3 study establishing the LAG-3 pathway as the third immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. This trial supported the FDA's approval of a new therapy for patients with advanced melanoma. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins. Dr. Lipson is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Pancreaticoduodenectomy.
Mgmc LLC
Geoffrey Gibney is a Hematologist and an Oncologist in Washington, Washington, D.c.. Dr. Gibney is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Olfactory Neuroblastoma, and Sinus Cancer.
Marc Ernstoff is an Oncologist in Frederick, Maryland. Dr. Ernstoff is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Renal Cell Carcinoma (RCC), Neuroendocrine Tumor, and Urothelial Cancer.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- MelanomaDr. Sharfman isElite. Learn about Melanoma.
- Merkel Cell CarcinomaDr. Sharfman isElite. Learn about Merkel Cell Carcinoma.
- Distinguished
- Eccrine PorocarcinomaDr. Sharfman isDistinguished. Learn about Eccrine Porocarcinoma.
- Familial Pancreatic CancerDr. Sharfman isDistinguished. Learn about Familial Pancreatic Cancer.
- Pancreatic CancerDr. Sharfman isDistinguished. Learn about Pancreatic Cancer.
- Advanced
- AngiosarcomaDr. Sharfman isAdvanced. Learn about Angiosarcoma.
- Breast CancerDr. Sharfman isAdvanced. Learn about Breast Cancer.
- Familial Colorectal CancerDr. Sharfman isAdvanced. Learn about Familial Colorectal Cancer.
- GliomaDr. Sharfman isAdvanced. Learn about Glioma.
- Melanoma of the EyeDr. Sharfman isAdvanced. Learn about Melanoma of the Eye.
- Neuroendocrine TumorDr. Sharfman isAdvanced. Learn about Neuroendocrine Tumor.
- Experienced
- Adult Soft Tissue SarcomaDr. Sharfman isExperienced. Learn about Adult Soft Tissue Sarcoma.
- ALK-Positive Non-Small Cell Lung CancerDr. Sharfman isExperienced. Learn about ALK-Positive Non-Small Cell Lung Cancer.
- Alveolar Soft Part SarcomaDr. Sharfman isExperienced. Learn about Alveolar Soft Part Sarcoma.
- Anal CancerDr. Sharfman isExperienced. Learn about Anal Cancer.
- Angiosarcoma of the ScalpDr. Sharfman isExperienced. Learn about Angiosarcoma of the Scalp.
- Basal Cell Skin CancerDr. Sharfman isExperienced. Learn about Basal Cell Skin Cancer.